Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?

被引:0
|
作者
Alpeeva, Elena [1 ]
Sukhanov, Yury [1 ]
Vorotelyak, Ekaterina [1 ]
机构
[1] Russian Acad Sci, Dept Cell Biol, NK Koltzov Inst Dev Biol, Vavilov Str 26, Moscow 119334, Russia
关键词
regenerative medicine; tissue engineering; skin equivalent; wound healing; clinical trials; marketing authorization; legislation; state strategy of development; REGENERATION; EPITHELIUM;
D O I
10.3390/biomedicines8020025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This review describes achievements of Russian cell-based regenerative medicine in different periods of time depending on the legislation and politics, and future prospects for its commercialization and wide application with an emphasis on products devised for skin regeneration. The world's experience in tissue engineering began with the development of living skin equivalents, utilizing a biopolymer matrix and cells at the very beginning of the 1980s. During this period, the USSR kept abreast with the times and also conducted studies on skin wound healing, implementing modern cell techniques. However, there soon emerged a gap between scientific advancement and practical application. After the breakup of the USSR, there were no institutions that could implement scientific inventions into full-scale manufacturing for clinical application. At the same time, accumulating scientific and practical experience allowed for the maintenance of biomedical research and its readiness for market entry at present. Recently developed legislation opens up new opportunities in this field in Russia. There are a growing number of studies on the development of novel products for regenerative medicine, bringing hope for its rapid progress.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Cardiovascular Tissue Engineering: Where We Come From and Where Are We Now?
    Smit, Francis E.
    Dohmen, Pascal M.
    MEDICAL SCIENCE MONITOR BASIC RESEARCH, 2015, 21 : 1 - 3
  • [2] Tissue engineering and regenerative medicine -where do we stand?
    Horch, Raymund E.
    Kneser, Ulrich
    Polykandriotis, Elias
    Schmidt, Volker J.
    Sun, Jiaming
    Arkudas, Andreas
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2012, 16 (06) : 1157 - 1165
  • [3] A narrative review of esophageal tissue engineering and replacement: where are we?
    Model, Lynn
    Wiesel, Ory
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (10)
  • [4] Tissue engineering of the urethra: where are we in 2019?
    Christopher Chapple
    World Journal of Urology, 2020, 38 : 2101 - 2105
  • [5] Tissue engineering in urology: Where are we going?
    Adam R. Metwalli
    James R. Colvert
    Bradley P. Kropp
    Current Urology Reports, 2003, 4 (2) : 156 - 163
  • [6] Intestinal tissue engineering: Where do we stand?
    Javaid-Ur-Rehman
    Waseem, Talat
    SURGERY TODAY, 2008, 38 (06) : 484 - 486
  • [7] Intestinal tissue engineering: Where do we stand?
    Talat Javaid-ur-Rehman
    Surgery Today, 2008, 38 : 484 - 486
  • [8] Ureteral Tissue Engineering: Where Are We and How to Proceed?
    Simaioforidis, Vasileios
    de Jonge, Paul
    Sloff, Marije
    Oosterwijk, Egbert
    Geutjes, Paul
    Feitz, Wout F. J.
    TISSUE ENGINEERING PART B-REVIEWS, 2013, 19 (05) : 413 - 419
  • [9] Artificial Intelligence and IBD: Where are We Now and Where Will We Be in the Future?
    Ahmed M.
    Stone M.L.
    Stidham R.W.
    Current Gastroenterology Reports, 2024, 26 (5) : 137 - 144
  • [10] Resveratrol supplementation: Where are we now and where should we go?
    Novelle, Marta G.
    Wahl, Devin
    Dieguez, Carlos
    Bernier, Michel
    de Cabo, Rafael
    AGEING RESEARCH REVIEWS, 2015, 21 : 1 - 15